Organometallic compounds in oncology: implications of novel organotins as antitumor agents

Angela Alama, Bruno Tasso, Federica Novelli, Fabio Sparatore

Research output: Contribution to journalArticle

Abstract

Since the introduction of cisplatin in cancer therapy, metal complexes and organometallic compounds have been gaining growing importance in oncology. The impressive clinical effectiveness of cisplatin is limited by significant side effects and the emergence of drug resistance. Thus, novel classic and unconventional PtII and PtIV complexes have been introduced in therapy or are presently in advanced clinical trials. Moreover, innovative non-platinum metal-based antitumor agents, whose activity does not rely on direct DNA damage and may involve proteins and enzymes, have been developed. Gold and tin derivatives are enjoying an increasing interest and appear very promising as potential drug candidates.

Original languageEnglish
Pages (from-to)500-508
Number of pages9
JournalDrug Discovery Today
Volume14
Issue number9-10
DOIs
Publication statusPublished - May 2009

Fingerprint

Organometallic Compounds
Antineoplastic Agents
Cisplatin
Tin
Coordination Complexes
Drug-Related Side Effects and Adverse Reactions
Drug Resistance
Gold
DNA Damage
Metals
Clinical Trials
Enzymes
Therapeutics
Pharmaceutical Preparations
Neoplasms
Proteins

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Organometallic compounds in oncology : implications of novel organotins as antitumor agents. / Alama, Angela; Tasso, Bruno; Novelli, Federica; Sparatore, Fabio.

In: Drug Discovery Today, Vol. 14, No. 9-10, 05.2009, p. 500-508.

Research output: Contribution to journalArticle

Alama, Angela ; Tasso, Bruno ; Novelli, Federica ; Sparatore, Fabio. / Organometallic compounds in oncology : implications of novel organotins as antitumor agents. In: Drug Discovery Today. 2009 ; Vol. 14, No. 9-10. pp. 500-508.
@article{7ad91bca7e9240eeac6a79d1e1542a02,
title = "Organometallic compounds in oncology: implications of novel organotins as antitumor agents",
abstract = "Since the introduction of cisplatin in cancer therapy, metal complexes and organometallic compounds have been gaining growing importance in oncology. The impressive clinical effectiveness of cisplatin is limited by significant side effects and the emergence of drug resistance. Thus, novel classic and unconventional PtII and PtIV complexes have been introduced in therapy or are presently in advanced clinical trials. Moreover, innovative non-platinum metal-based antitumor agents, whose activity does not rely on direct DNA damage and may involve proteins and enzymes, have been developed. Gold and tin derivatives are enjoying an increasing interest and appear very promising as potential drug candidates.",
author = "Angela Alama and Bruno Tasso and Federica Novelli and Fabio Sparatore",
year = "2009",
month = "5",
doi = "10.1016/j.drudis.2009.02.002",
language = "English",
volume = "14",
pages = "500--508",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "9-10",

}

TY - JOUR

T1 - Organometallic compounds in oncology

T2 - implications of novel organotins as antitumor agents

AU - Alama, Angela

AU - Tasso, Bruno

AU - Novelli, Federica

AU - Sparatore, Fabio

PY - 2009/5

Y1 - 2009/5

N2 - Since the introduction of cisplatin in cancer therapy, metal complexes and organometallic compounds have been gaining growing importance in oncology. The impressive clinical effectiveness of cisplatin is limited by significant side effects and the emergence of drug resistance. Thus, novel classic and unconventional PtII and PtIV complexes have been introduced in therapy or are presently in advanced clinical trials. Moreover, innovative non-platinum metal-based antitumor agents, whose activity does not rely on direct DNA damage and may involve proteins and enzymes, have been developed. Gold and tin derivatives are enjoying an increasing interest and appear very promising as potential drug candidates.

AB - Since the introduction of cisplatin in cancer therapy, metal complexes and organometallic compounds have been gaining growing importance in oncology. The impressive clinical effectiveness of cisplatin is limited by significant side effects and the emergence of drug resistance. Thus, novel classic and unconventional PtII and PtIV complexes have been introduced in therapy or are presently in advanced clinical trials. Moreover, innovative non-platinum metal-based antitumor agents, whose activity does not rely on direct DNA damage and may involve proteins and enzymes, have been developed. Gold and tin derivatives are enjoying an increasing interest and appear very promising as potential drug candidates.

UR - http://www.scopus.com/inward/record.url?scp=67349260256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349260256&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2009.02.002

DO - 10.1016/j.drudis.2009.02.002

M3 - Article

C2 - 19429510

AN - SCOPUS:67349260256

VL - 14

SP - 500

EP - 508

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 9-10

ER -